About Zura Bio Limited
https://zurabio.comZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
CEO
Robert Lisicki
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 3
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:5.47M
Value:$29.39M
VR ADVISER, LLC
Shares:4.63M
Value:$24.87M
JPMORGAN CHASE & CO
Shares:4.62M
Value:$24.83M
Summary
Showing Top 3 of 72
About Zura Bio Limited
https://zurabio.comZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $19.52M ▲ | $-20.04M ▼ | 0% | $-0.21 ▼ | $-18.03M ▲ |
| Q2-2025 | $0 | $18.06M ▼ | $-15.99M ▲ | 0% | $-0.17 ▲ | $-18.05M ▲ |
| Q1-2025 | $0 | $19.25M ▲ | $-17.44M ▼ | 0% | $-0.19 ▼ | $-19.25M ▼ |
| Q4-2024 | $0 | $15.73M ▼ | $-9.05M ▲ | 0% | $-0.14 ▲ | $-13.62M ▲ |
| Q3-2024 | $0 | $19.32M | $-20.7M | 0% | $-0.26 | $-19.32M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $139.02M ▼ | $143.94M ▼ | $25.49M ▲ | $108.24M ▼ |
| Q2-2025 | $154.49M ▼ | $157.81M ▼ | $18.7M ▼ | $125.91M ▼ |
| Q1-2025 | $170.57M ▼ | $172.5M ▼ | $21.09M ▲ | $138.2M ▼ |
| Q4-2024 | $176.5M ▼ | $179.53M ▼ | $19.51M ▲ | $146.81M ▼ |
| Q3-2024 | $188.22M | $189.07M | $18.24M | $153.05M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-20.04M ▼ | $-15.44M ▲ | $-32K ▼ | $3K ▲ | $-15.47M ▲ | $-15.48M ▲ |
| Q2-2025 | $-15.99M ▲ | $-16.03M ▼ | $-15K ▲ | $-34K ▼ | $-16.08M ▼ | $-16.05M ▼ |
| Q1-2025 | $-17.44M ▼ | $-11.06M ▼ | $-49K ▼ | $5.18M ▲ | $-5.93M ▲ | $-11.11M ▼ |
| Q4-2024 | $-11.29M ▲ | $-10.82M ▼ | $-45K ▼ | $-854K ▼ | $-11.72M ▼ | $-10.87M ▼ |
| Q3-2024 | $-20.7M | $-5.65M | $-13K | $5.44M | $-222K | $-5.67M |
CEO
Robert Lisicki
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 3
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:5.47M
Value:$29.39M
VR ADVISER, LLC
Shares:4.63M
Value:$24.87M
JPMORGAN CHASE & CO
Shares:4.62M
Value:$24.83M
Summary
Showing Top 3 of 72